Safer prescribing for childrenBMJ 2005; 331 doi: https://doi.org/10.1136/bmj.331.7518.646 (Published 22 September 2005) Cite this as: BMJ 2005;331:646
- Harvey Marcovitch (firstname.lastname@example.org), associate editor
Will be boosted by European and US laws and the new British national formulary for children
Paediatric prescribing can be precise, beneficial, and safe. It can also be confusing, based on little or no evidence of effectiveness, and can put children at risk. The nature of marketing authorisations (formerly product licences) for drugs merely enhances the paradox. They were designed as a means of obtaining approval for use by an appropriate regulatory body, usually a government agency; so the decision to apply for authorisation is influenced more by commercial than clinical considerations.1 One result is that unlicensed and “off label” prescribing is common. Paediatricians, general practitioners, and others are torn between providing treatment which their experience and reason have deemed suitable and denying it because of the lack of research data underpinning indications, dosages, or formulations. …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial